Document is current

Article History

Received: 4 June 2024

Accepted: 27 August 2024

First Online: 17 September 2024

Declarations

:

: Takao Hirano reports receiving advisory board and medical writing consulting fees from Novartis Pharma K.K., and lecture fees from Bayer Yakuhin, Canon Inc, Kowa Pharmaceutical, Novartis Pharma K.K., Senju Pharmaceutical, Santen, and Chugai Pharmaceutical. Toshinori Murata reports receiving advisory board and medical writing consulting fees from Novartis Pharma and lecture fees from Novartis Pharma, Bayer AG, Santen Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd, Zeiss Meditec and Canon Inc. Koji Tanabe was affiliated with Novartis Pharma K.K. at the time of the study but is now affiliated with Novo Nordisk Pharma Ltd. The funder participated in the design and conduct of the study; data collection, management, and analysis; interpretation of the data; and preparation, review, and approval of the manuscript.

: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Medical Corporation Toukeikai Kitamachi Clinic Institutional Review Board (BGQ08442, September 15, 2021). Online informed consent was obtained from all subjects involved in the study. By signing the Information and Consent document, study participants are authorizing access to their records.